Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a simple cream shield cancer patients from radiation burns?

NCT ID NCT07545720

First seen Apr 28, 2026 · Last updated Jun 21, 2026 · Updated 12 times

Summary

This study tests a cream called Pinoxin to see if it can prevent skin injuries caused by radiation therapy in cancer patients. About 202 adults receiving high-dose radiation will be randomly assigned to use either Pinoxin or a placebo cream. The main goal is to see if Pinoxin lowers the rate of moderate to severe skin burns.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT TUMOR are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fudan University Shanghai Cancer Center

    RECRUITING

    Shanghai, Shanghai Municipality, 200032, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Fudan University Shanghai Cancer Center

    RECRUITING

    Shanghai, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Pinoxin (a hydrogen-donor modified SOD skin protective agent)

What this could lead to

If it works, this could provide a simple preventive cream to reduce painful skin burns for cancer patients undergoing radiation therapy.

What could go wrong

This is a Phase 2 trial with 202 participants, so it is still early. The placebo group may show similar results, and the cream may not reduce severe skin injury as hoped.

Conditions

The condition(s) this trial relates to.

cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.